New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders

Neurodegenerative diseases are often consideredincurable with no efficient therapies to modifyor halt the progress of disease, and ultimatelylead to reduced quality of life and to death.Our knowledge of the nervous system in healthand disease has, however, increasedconsiderably during the last fifty years andtoday, neuroscience reveals promising newstrategies to deal with disorders of thenervous system.Some of these results have been implementedwith success in the treatment of Parkinson'sdisease, a common neurodegenerative illnessaffecting approximately 1% of the populationaged seventy or more. Parkinson's disease ischaracterized by a massive loss of dopaminergicneurons in the substantia nigra, leading tosevere functional disturbance of the neuronalcircuitry in the basal ganglia. A thoroughdescription of basal ganglia circuitry inhealth and disease is presented. We describehow the functional disturbances seen inParkinson's disease may be corrected atspecific sites in this circuitry by medicaltreatment or, in advanced stages of Parkinson'sdisease, by neurosurgical methods. The latterinclude lesional surgery, neuraltransplantation and deep brain stimulation,together with future treatment strategies usingdirect or indirect implantation of geneticallymodified cell-lines capable of secretingneurotrophic factors or neurotransmitters.Advantages and disadvantages are brieflymentioned for each strategy and theimplications for the future and the possibleuse of these interventions in otherneurodegenerative diseases are discussed, withspecial emphasis on deep brain stimulation.

[1]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[2]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[3]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[4]  J. Dostrovsky,et al.  Methods for microelectrode-guided posteroventral pallidotomy. , 1996, Journal of neurosurgery.

[5]  C. Marsden,et al.  Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.

[6]  H. Widner The case for neural tissue transplantation as a treatment for Parkinson's disease. , 1999, Advances in neurology.

[7]  L. Hansson,et al.  Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease , 1998, Acta neurologica Scandinavica.

[8]  S. Aquilonius,et al.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease , 2004, European Journal of Clinical Pharmacology.

[9]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[10]  G. E. Alexander,et al.  Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.

[11]  Å. Bertler,et al.  Occurrence and distribution of catechol amines in brain. , 1959, Acta physiologica Scandinavica.

[12]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[13]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Economo Die Encephalitis lethargica , 1918 .

[15]  J. O. Dostrovsky,et al.  Thalamotomy for Parkinson’s Disease: Microelectrode Technique , 1988 .

[16]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[17]  B. Lippitz,et al.  Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. , 1994, Neurosurgery.

[18]  A. Benabid,et al.  Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. , 1987, Applied neurophysiology.

[19]  E. Spiegel,et al.  Ansotomy in paralysis agitans. , 1954, A.M.A. archives of neurology and psychiatry.

[20]  G. Meco,et al.  Familial Parkinson’s Disease: A Clinical Genetic Analysis , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[21]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[22]  C. Clough,et al.  Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. , 1991, Archives of neurology.

[23]  R. Duvoisin,et al.  ENCEPHALITIS AND PARKINSONISM. , 1965, Archives of neurology.

[24]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[25]  J. Trojanowski,et al.  Neuropathology of synuclein aggregates , 2000, Journal of neuroscience research.

[26]  A. Carlsson,et al.  The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.

[27]  J. Nutt,et al.  Increased risk of Parkinson's disease in parents and siblings of patients , 1994, Annals of neurology.

[28]  C. Tanner Epidemiology of Parkinson’s Disease , 1992, Neurologic Clinics.

[29]  D. Guehl,et al.  High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. , 1997, Journal of neurosurgery.

[30]  H. Przuntek,et al.  Effect of selegiline on mortality in patients with Parkinson's disease , 1998, Neurology.

[31]  A. Bjo¨rklund,et al.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants , 1979, Brain Research.

[32]  C. Camp PATHOLOGY OF PARALYSIS AGITANS. , 1907 .

[33]  A. Björklund,et al.  Generation of DOPA-Producing Astrocytes by Retroviral Transduction of the Human Tyrosine Hydroxylase Gene:In VitroCharacterization andin VivoEffects in the Rat Parkinson Model , 1996, Experimental Neurology.

[34]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[35]  J. Speelman,et al.  O-18-264 Thalamic stimulation versus thalamotomy in a prospective randomized trial , 1997, Clinical Neurology and Neurosurgery.

[36]  J. Obeso,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.

[37]  J. Dostrovsky,et al.  Effect of GPi pallidotomy on motor function in Parkinson's disease , 1995, The Lancet.

[38]  André Parent,et al.  Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity , 1988, Brain Research.

[39]  A. Benabid,et al.  Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus , 1991, The Lancet.

[40]  M. Hariz Current controversies in pallidal surgery. , 1999, Advances in neurology.

[41]  I. Cooper,et al.  Surgical treatment of parkinsonism. , 1961, British medical journal.

[42]  R. Duvoisin Genetic and environmental factors in Parkinson's disease. , 1999, Advances in neurology.

[43]  J. Dostrovsky,et al.  Deep brain stimulation and thalamotomy for tremor compared. , 1997, Acta neurochirurgica. Supplement.

[44]  B. Snow,et al.  The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.

[45]  I. Ziv,et al.  Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. , 1999, Advances in neurology.

[46]  Scott T. Grafton,et al.  Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. , 1990, Archives of neurology.

[47]  A. Parent,et al.  Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.

[48]  A. Dagher,et al.  Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. , 2000, Journal of neurosurgery.

[49]  A. Björklund,et al.  Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. , 1996, Neuroscience.

[50]  H. Bergman,et al.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.

[51]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[52]  Richard S. J. Frackowiak,et al.  Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study , 1992, Annals of neurology.

[53]  S. Mandel,et al.  Apomorphine protects against MPTP‐induced neurotoxicity in mice , 1999, Movement disorders : official journal of the Movement Disorder Society.

[54]  G. E. Alexander Basal Ganglia‐Thalamocortical Circuits: Their Role in Control of Movements , 1994, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[55]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[56]  J. A. Obeso,et al.  Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease , 1994, The Lancet.

[57]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[58]  M. Youdim,et al.  Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐Hydroxydopamine , 1998, Movement disorders : official journal of the Movement Disorder Society.

[59]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[60]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[61]  A. Björklund,et al.  Immortalized neural progenitor cells for CNS gene transfer and repair , 1997, Trends in Neurosciences.

[62]  L. J. Fisher,et al.  In vivo and ex vivo gene transfer to the brain , 1994, Current Opinion in Neurobiology.

[63]  R. Turner,et al.  Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot study , 1996, Annals of neurology.

[64]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[65]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[66]  V. Kostic,et al.  Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease , 1991, Neurology.

[67]  W Fernandez,et al.  Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine , 1992, Annals of neurology.

[68]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[69]  M. Hariz,et al.  Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. , 1992, Journal of neurosurgery.

[70]  B J Hoffer,et al.  Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. , 1989, Archives of neurology.

[71]  T. Deacon,et al.  Xenotransplantation of Porcine Fetal Ventral Mesencephalon in a Rat Model of Parkinson's Disease: Functional Recovery and Graft Morphology , 1996, Experimental Neurology.

[72]  C. Marsden,et al.  A clinical and genetic study of familial Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.

[73]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[74]  A. Lang,et al.  Posteroventral medial pallidotomy in advanced Parkinson's disease. , 1997, New England Journal of Medicine.

[75]  J. Yelnik Functional anatomy of the basal ganglia , 2002, Movement disorders : official journal of the Movement Disorder Society.

[76]  A L Benabid,et al.  Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. , 1998, Brain : a journal of neurology.

[77]  S. Kuniyoshi,et al.  Electrophysiologic target localization in posteroventral pallidotomy , 2005, Acta Neurochirurgica.

[78]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[79]  A. Benabid,et al.  Opposite motor effects of pallidal stimulation in Parkinson's disease , 1998, Annals of neurology.

[80]  S. Horai,et al.  Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.

[81]  L. Golbe,et al.  A clinical genetic study of Parkinson's disease , 1994, Neurology.

[82]  J. Jankovic,et al.  Surgical treatment of levodopa-induced dyskinesias. , 1999, Advances in neurology.

[83]  S. Dunnett Transplantation of embryonic dopamine neurons: what we know from rats , 1991, Journal of Neurology.

[84]  S. Roy,et al.  Parkinson's disease in a Scottish city. , 1986, British medical journal.

[85]  S. Rietbrock,et al.  Concentration-Effect Relationship of Levodopa in Patients with Parkinson’s Disease , 1995, Clinical pharmacokinetics.

[86]  M. Chesselet,et al.  Basal ganglia and movement disorders: an update , 1996, Trends in Neurosciences.

[87]  E Kanal,et al.  A comparison between magnetic resonance imaging and computed tomography for stereotactic coordinate determination. , 1992, Neurosurgery.

[88]  Ole Isacson,et al.  Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease , 1997, Nature Medicine.

[89]  J. Guieu,et al.  Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. , 1992, Journal of neurosurgery.

[90]  S. Aquilonius,et al.  Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease , 2004, European Journal of Clinical Pharmacology.

[91]  C. Tanner,et al.  The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.

[92]  Richard S. J. Frackowiak,et al.  Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease , 1994, Annals of neurology.

[93]  J. Nutt On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics , 1987, Annals of neurology.

[94]  P. Brundin,et al.  Lazaroids improve the survival of grafted rat embryonic dopamine neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[95]  S. Wiegand,et al.  BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine Neurons , 1996, Experimental Neurology.

[96]  Patrik Brundin,et al.  Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis , 1988, Brain Research Reviews.

[97]  G K Wenning,et al.  Apomorphine: An underutilized therapy for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[98]  A. Lees,et al.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease , 1995, BMJ.

[99]  A. Parent,et al.  Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitry , 1995, Brain Research Reviews.

[100]  J. Larsen,et al.  Does selegiline modify the progression of early Parkinson's disease? Results from a five‐year study , 1999, European journal of neurology.

[101]  O. Lindvall Neural transplantation: can we improve the symptomatic relief? , 1999, Advances in neurology.

[102]  M. Merello,et al.  [Functional anatomy of the basal ganglia]. , 2000, Revista de neurologia.

[103]  D. Perl,et al.  Projected neurodegenerative disease mortality in the United States, 1990-2040. , 1993, Neuroepidemiology.

[104]  D. Maraganore Epidemiology and Genetics of Parkinson’s Disease , 2000 .

[105]  A. Benabid,et al.  Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. , 1996, Journal of neurosurgery.

[106]  L. Leksell,et al.  TREATMENT OF PARKINSONISM BY STEREOTACTIC THERMOLESIONS IN THE PALLIDAL REGION. A clinical evaluation of 81 cases. , 1960, Acta psychiatrica Scandinavica.

[107]  S. Fahn,et al.  Selegiline and mortality in Parkinson's disease , 1996, Annals of neurology.

[108]  A. Carlsson,et al.  On the presence of 3-hydroxytyramine in brain. , 1958, Science.

[109]  A. Benabid,et al.  Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation , 1995, The Lancet.

[110]  G. Boer,et al.  Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research , 1994, Journal of Neurology.

[111]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[112]  A. Björklund,et al.  Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release , 1988, Experimental Brain Research.

[113]  L. Descarries,et al.  Distribution of GABA‐immunoreactive neurons in the basal ganglia of the squirrel monkey (Saimiri sciureus) , 1987, The Journal of comparative neurology.

[114]  Ornella Rimoldi,et al.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.

[115]  S. Konitsiotis,et al.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.

[116]  G. Selby Stereotactic surgery for the relief of Parkinson's disease , 1967 .

[117]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[118]  F. J. Gillingham,et al.  The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study. , 1980, Journal of neurosurgery.

[119]  G. Wooten,et al.  Maternal inheritance in Parkinson's disease , 1997, Annals of neurology.

[120]  O. Lindvall Clinical application of neuronal grafts in Parkinson's disease , 1994, Journal of Neurology.

[121]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[122]  C. Gerfen The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. , 1992, Annual review of neuroscience.

[123]  C. C. Johnson,et al.  Parkinson's disease mortality and the industrial use of heavy metals in Michigan , 1993, Movement disorders : official journal of the Movement Disorder Society.

[124]  W. Freed Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutic trials. , 1991, Restorative neurology and neuroscience.

[125]  Richard S. J. Frackowiak,et al.  Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease , 1997, Annals of neurology.

[126]  K. Planansky Paralysis agitans: A clinical and genetic study , 1950 .

[127]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.